Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16712668rdf:typepubmed:Citationlld:pubmed
pubmed-article:16712668lifeskim:mentionsumls-concept:C0015576lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0025268lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0205147lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C2745955lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0694890lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C1833929lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0205099lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0032729lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C1706204lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:16712668lifeskim:mentionsumls-concept:C1555721lld:lifeskim
pubmed-article:16712668pubmed:issue6lld:pubmed
pubmed-article:16712668pubmed:dateCreated2006-5-22lld:pubmed
pubmed-article:16712668pubmed:abstractTextMedullary thyroid carcinoma (MTC) occurs both sporadically and in the context of autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN2) syndromes: MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC), which are caused by activating germline mutations in the RET proto-oncogene. The aim of this study was to characterize the RET mutational spectrum in MEN2 families and apparently sporadic MTC (AS-MTC) cases originating from the central region of Portugal.lld:pubmed
pubmed-article:16712668pubmed:languageenglld:pubmed
pubmed-article:16712668pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16712668pubmed:citationSubsetIMlld:pubmed
pubmed-article:16712668pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16712668pubmed:statusMEDLINElld:pubmed
pubmed-article:16712668pubmed:monthJunlld:pubmed
pubmed-article:16712668pubmed:issn0300-0664lld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:BugalhoMaria...lld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:SoaresPaulaPlld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:RodriguesFern...lld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:CamposBeatriz...lld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:LacerdaManuel...lld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:FigueiredoPau...lld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:PrazeresHugo...lld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:NaidenovPlame...lld:pubmed
pubmed-article:16712668pubmed:authorpubmed-author:MartinsTeresa...lld:pubmed
pubmed-article:16712668pubmed:issnTypePrintlld:pubmed
pubmed-article:16712668pubmed:volume64lld:pubmed
pubmed-article:16712668pubmed:ownerNLMlld:pubmed
pubmed-article:16712668pubmed:authorsCompleteYlld:pubmed
pubmed-article:16712668pubmed:pagination659-66lld:pubmed
pubmed-article:16712668pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:meshHeadingpubmed-meshheading:16712668...lld:pubmed
pubmed-article:16712668pubmed:year2006lld:pubmed
pubmed-article:16712668pubmed:articleTitleOccurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.lld:pubmed
pubmed-article:16712668pubmed:affiliationMolecular Pathology Laboratory, Regional Centre of Oncology of Coimbra, Portuguese Institute of Oncology, Coimbra, Portugal. upmolecular@croc.min-saude.ptlld:pubmed
pubmed-article:16712668pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16712668pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed